Copyright 2009 Medical News Today Latest Lung Cancer News From Medical News Today. http://www.medicalnewstoday.com/sections/lung_cancer/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170192.php http://www.medicalnewstoday.com/articles/170192.php Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th. Lung Cancer Sat, 07 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/170194.php http://www.medicalnewstoday.com/articles/170194.php A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. In addition, the researchers also found that the higher the metabolic activity and tumor size on a PET scan before treatment, the more likely a patient is to die from lung cancer. Lung Cancer Wed, 04 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169772.php http://www.medicalnewstoday.com/articles/169772.php Patients with early stage, non-small cell lung cancer who are not able to undergo surgery, now have a highly effective treatment option. Physicians say that option, radical stereotactic radiosurgery performed with CyberKnife, leads to a 100 percent overall survival after three years in patients with good lung function before treatment. These are the results of a study presented at the annual CHEST meeting in San Diego. Lung Cancer Wed, 04 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169818.php http://www.medicalnewstoday.com/articles/169818.php Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186). Lung Cancer Wed, 04 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169726.php http://www.medicalnewstoday.com/articles/169726.php The NHS is still failing lung cancer patients, according to the results of the first national review of lung cancer services, published this Monday.1 Despite headway in UK lung cancer prevention, disease awareness and screening, key areas such as diagnosis, treatment rates and access to specialists are still 'woefully inadequate' say the UK's leading lung cancer experts. Lung Cancer Tue, 03 Nov 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/169654.php http://www.medicalnewstoday.com/articles/169654.php A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study results show that while preventative brain radiation for patients with non-small cell lung cancer - the most common form of lung cancer - does reduce the chance of developing brain metastases, it impacts some short-term and long-term memory. Lung Cancer Tue, 03 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169642.php http://www.medicalnewstoday.com/articles/169642.php Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). Lung Cancer Tue, 03 Nov 2009 04:00:00 PST http://www.medicalnewstoday.com/articles/169626.php http://www.medicalnewstoday.com/articles/169626.php Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Lung Cancer Tue, 03 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/169530.php http://www.medicalnewstoday.com/articles/169530.php Patients with non-small cell lung cancer treated with preventative brain radiation (called prophylactic cranial irradiation or PCI), significantly decrease their risk of developing brain metastases (cancer spread in the brain) by more than 50 percent (from 18 percent to 8 percent), compared to th Lung Cancer Mon, 02 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169465.php http://www.medicalnewstoday.com/articles/169465.php A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Initiated in 2001, the current study confirmed 18 cases of cancer of the original 430 patients who qualified as high risk after completing a five-minute questionnaire. The study was conducted in primary care physician offices among patients seeking care for general health issues. Lung Cancer Mon, 02 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/169466.php http://www.medicalnewstoday.com/articles/169466.php Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. To gain better insight on this topic, researchers studied the timing of lung cancer diagnosis and treatment at a U.S. medical center providing care to a diverse patient population within two different hospital systems. David E. Lung Cancer Sat, 31 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/169352.php http://www.medicalnewstoday.com/articles/169352.php Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Lung Cancer Fri, 30 Oct 2009 13:00:00 PST http://www.medicalnewstoday.com/articles/169333.php http://www.medicalnewstoday.com/articles/169333.php The European Medicines Agency has been formally notified by AstraZeneca of its decision to withdraw its application for a centralised marketing authorisation for the medicine Zactima (vandetinib), 100 mg film-coated tablets. Zactima was expected to be used in combination with chemotherapy, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received prior anticancer therapy. Lung Cancer Fri, 30 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/169312.php http://www.medicalnewstoday.com/articles/169312.php 4 news briefings with live webcast previewing studies The American Society for Radiation Oncology (ASTRO) will host four news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting. News briefing 1 When: Monday, November 2, at 8:00 a.m. (Central); 9:00 a.m. (Eastern) What: News briefing with live webcast from ASTRO's 51st Annual Meeting. Lung Cancer Thu, 29 Oct 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/169100.php http://www.medicalnewstoday.com/articles/169100.php Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year.(1) It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined. Lung Cancer Sat, 24 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/168572.php http://www.medicalnewstoday.com/articles/168572.php Biomoda, Inc. (OTC Bulletin Board: BMOD), a diagnostics company focused on the development of accurate, inexpensive and noninvasive in-vitro tests for the early detection of cancer, has met its recruitment goal for New Mexico veterans with a history of heavy smoking required to complete the Phase II clinical trial of Biomoda's early-stage diagnostic for lung cancer. Lung Cancer Thu, 22 Oct 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/168346.php http://www.medicalnewstoday.com/articles/168346.php Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. Pancreatic Cancer Mon, 19 Oct 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/167794.php http://www.medicalnewstoday.com/articles/167794.php The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others. It is unknown if EGFR and HER2 are overexpressed in advanced biliary tract cancer (BTC) and therefore may serve as therapeutic targets in these cancers. GastroIntestinal / Gastroenterology Fri, 16 Oct 2009 07:00:00 PST http://www.medicalnewstoday.com/articles/167646.php http://www.medicalnewstoday.com/articles/167646.php Med BioGene Inc. (TSX VENTURE:MBI) today announced positive results from the current validation study of LungExpress DxTM undertaken by MBI and its collaborators at the University Health Network (Princess Margaret Hospital) in Toronto. Lung Cancer Tue, 13 Oct 2009 20:00:00 PST http://www.medicalnewstoday.com/articles/167200.php http://www.medicalnewstoday.com/articles/167200.php Phyton Biotech GmbH, a world leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing taxanes such as paclitaxel. Paclitaxel, the active ingredient in Bristol-Myers Squibb's TAXOL®, is useful in the treatment of breast, ovarian, lung, and other forms of cancer. Cancer / Oncology Mon, 12 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/167044.php http://www.medicalnewstoday.com/articles/167044.php A new technique in Magnetic Resonance Imaging dubbed "Hyper-SAGE" has the potential to detect ultra low concentrations of clincal targets, such as lung and other cancers. Development of Hyper-SAGE was led by one of the world's foremost authorities on MRI technology, Alexander Pines, a chemist who holds joint appointments with the Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California, Berkeley. MRI / PET / Ultrasound Fri, 09 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/166757.php http://www.medicalnewstoday.com/articles/166757.php Using computer modeling, the Translational Genomics Research Institute and Scottsdale Healthcare have discovered lung cancer 'pathways' that could become targets for new drugs, according to a scientific paper published online by the Journal of Thoracic Oncology. Dr. Glen Weiss, Director of Thoracic Oncology at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare, said the study showed the value of conducting computer modeling, or "in silico" research. Lung Cancer Thu, 08 Oct 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/166706.php http://www.medicalnewstoday.com/articles/166706.php Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. Lung Cancer Tue, 06 Oct 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/166255.php http://www.medicalnewstoday.com/articles/166255.php Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria. Lung Cancer Mon, 05 Oct 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/166163.php http://www.medicalnewstoday.com/articles/166163.php The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010. Lung Cancer